GERN
Geron Corp Health Care Pharmaceutical Preparations Russell 3000
$0.89Close
$569.5MMarket cap
$0.89 – $1.9552-week range
Nov 4, 2026Next report · before the open
Highlights
Cautions
- Not in an uptrend 0 of 8 trend conditions
- Lagging the market RS 7 · weaker than 93% of stocks over 12 months
- Far from its high 54% below its 52-week high
- Distribution down-day volume 3.0× up-day volume over 50 sessions
- Results soon Nov 4, 2026, in 3 days
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
54%
1wk
down 20.5%
price change
1mo
down 27.6%
price change
12-month return
down 28%
market up 11% ·
its own down 38%
F-score
—
— Not assessed
Altman Z
—
Unknown
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
2.5×
price / book
Earnings yield
down 11.2%
EBIT / enterprise value
Cheaper than
—
of the market · not assessed
Revenue growth
—
year on year
EPS growth
—
latest quarter
Sales growth
up 17%
latest quarter · -14 pts
ROE
down 33%
return on equity
Free cash margin
—
-$111.0M FCF
D/E
0.53
long-term debt / equity
Net debt / EBITDA
—
Interest cover
—EBIT / interest
Trade setup
ATR%
9.0%
$0.08 a day · 2×ATR $0.73
RS
7 / 99
vs the universe
Trend
0 / 8
trend template
Relative volume
1.7×
vs 50-day average
Up/down volume
0.34
50 sessions
Implied move
—
no option chain · report Nov 4, 2026
Trend template · 0 of 8
Screen verdict
Did not qualify for any screen.
Warning signs
- Shareholders diluted The share count rose 5.5% over the year, from 606m to 640m shares. Each existing share owns a smaller fraction of the company than it did a year ago.
Last reported
Aug 6, 2026
Last shock
Oct 28, 2026-16% in one session7.7× volumeon an SEC filing-8% since
Financials
- Net
- Free cash
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $253,000 | $1.4M | $596,000 | $237,000 | — | — |
| Operating income | -$76.9M | -$114.0M | -$138.6M | -$193.9M | -$173.7M | -$68.6M |
| Net income | -$75.6M | -$116.1M | -$141.9M | -$184.1M | -$174.6M | -$83.5M |
| Net margin | -29888% | -8335% | -23809% | -77691% | — | — |
| Earnings per share | -$0.28 | -$0.35 | -$0.37 | -$0.32 | -$0.27 | -$0.13 |
| Free cash flow | -$67.1M | -$95.8M | -$127.8M | -$168.6M | -$219.3M | -$111.0M |
| Free cash margin | -26503% | -6875% | -21445% | -71128% | — | — |
| Cash | $9.9M | $34.9M | $56.8M | $70.0M | $79.0M | $77.6M |
| Long-term debt | $24.0M | $49.8M | $30.2M | $35.1M | $118.5M | $119.5M |
| Shareholders' equity | $210.9M | $126.4M | $80.0M | $247.9M | $280.3M | $225.9M |
| Shares outstanding | 310.57m | 323.73m | 390.26m | 544.91m | 606.39m | 639.86m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 5, 2026 | Quarterly ↗ | Jun 30, 2026 | 36d |
| May 6, 2026 | Quarterly ↗ | Mar 31, 2026 | 36d |
| Mar 2, 2026 | Annual ↗ | Dec 31, 2025 | 61d |
| Nov 7, 2025 | Quarterly ↗ | Sep 30, 2025 | 38d |
| Aug 6, 2025 | Quarterly ↗ | Jun 30, 2025 | 37d |
| May 7, 2025 | Quarterly ↗ | Mar 31, 2025 | 37d |
| Feb 27, 2025 | Annual ↗ | Dec 31, 2024 | 58d |
| Nov 7, 2024 | Quarterly ↗ | Sep 30, 2024 | 38d |
| Aug 8, 2024 | Quarterly ↗ | Jun 30, 2024 | 39d |
| May 2, 2024 | Quarterly ↗ | Mar 31, 2024 | 32d |
| Feb 28, 2024 | Annual ↗ | Dec 31, 2023 | 59d |
| Nov 2, 2023 | Quarterly ↗ | Sep 30, 2023 | 33d |
Current reports
| Filed | Disclosed |
|---|---|
| Oct 28, 2026 | Other events ↗ |
| Aug 6, 2026 | Results ↗ |
| May 27, 2026 | Director or officer change · Shareholder vote ↗ |
| Mar 26, 2026 | Director or officer change ↗ |
| Feb 25, 2026 | Results ↗ |
| Jan 12, 2026 | Regulation FD ↗ |
| Jan 6, 2026 | Material agreement ↗ |
| Dec 16, 2025 | Restructuring ↗ |
| Nov 5, 2025 | Results ↗ |
| Oct 14, 2025 | Director or officer change · Regulation FD ↗ |
| Aug 6, 2025 | Director or officer change ↗ |
| Aug 6, 2025 | Results ↗ |